In the transverse aortic constriction model, which causes pressure overload, ventricular compensation, and heart failure, studies have reported improvements with GLP-1 medicines in ventricular hypertrophy associated with reduced inflammation in rodents (58, 59), although none of these studies addresses the potential site(s) of GLP-1 action. Here, GLP1R is linked to Ventricular hypertrophy.